Randomized phase II trial of parsatuzumab (Anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab for first-line metastatic colorectal cancer

  1. García-Carbonero, R.
  2. Van Cutsem, E.
  3. Rivera, F.
  4. Jassem, J.
  5. Gore, I.
  6. Tebbutt, N.
  7. Braiteh, F.
  8. Argiles, G.
  9. Wainberg, Z.A.
  10. Funke, R.
  11. Anderson, M.
  12. McCall, B.
  13. Stroh, M.
  14. Wakshull, E.
  15. Hegde, P.
  16. Ye, W.
  17. Chen, D.
  18. Chang, I.
  19. Rhee, I.
  20. Hurwitz, H.
Revista:
Oncologist

ISSN: 1549-490X,  1083-7159

Any de publicació: 2017

Volum: 22

Número: 4

Tipus: Article

DOI: 10.1634/THEONCOLOGIST.2016-0133 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus